Insider Buying: Zura Bio Limited (NASDAQ:ZURA) EVP Purchases $10,000.35 in Stock

Zura Bio Limited (NASDAQ:ZURA) EVP Kiran Nistala acquired 3,195 shares of the firm’s stock in a transaction dated Monday, April 22nd. The stock was bought at an average cost of $3.13 per share, with a total value of $10,000.35. Following the acquisition, the executive vice president now owns 3,195 shares in the company, valued at $10,000.35. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Zura Bio Trading Up 21.8 %

Shares of Zura Bio stock opened at $4.41 on Friday. Zura Bio Limited has a fifty-two week low of $2.00 and a fifty-two week high of $14.00. The stock has a 50 day moving average of $3.19 and a 200 day moving average of $4.01.

Wall Street Analyst Weigh In

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $16.00 price target (down previously from $17.00) on shares of Zura Bio in a report on Monday, April 1st. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $16.40.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Lynx1 Capital Management LP acquired a new stake in shares of Zura Bio in the third quarter valued at $65,000. Forefront Analytics LLC acquired a new stake in shares of Zura Bio in the third quarter valued at $95,000. Bank of New York Mellon Corp acquired a new stake in shares of Zura Bio in the third quarter valued at $224,000. Raymond James & Associates raised its stake in shares of Zura Bio by 14.0% in the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock valued at $511,000 after acquiring an additional 9,481 shares in the last quarter. Finally, Eisler Capital US LLC acquired a new stake in shares of Zura Bio in the third quarter valued at $660,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.